2 weeks Ago By ABMN Staff
AbbVie Inc. ( NYSE:ABBV – Free Report ) – Equities research analysts at Leerink Partnrs increased their FY2025 EPS estimates for AbbVie in a report released on Wednesday, August 28th. Leerink Partnrs analyst D.
Risinger now expects that the company will post earnings of $12.11 per share for the year, up from their prior forecast of $11.55.
The consensus estimate for AbbVie’s current full-year earnings is $10.87 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2026 earnings at $13.
41 EPS, FY2027 earnings at $15.03 EPS and FY2028 earnings at $16.24 EPS.
AbbVie ( NYSE:ABBV – Get Free Report ) last issued its earnings results on Thursday, July 25th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.
57 by $0.08. AbbVie had a net margin of 9.
71% and a return on equity of 186.82%. The business had revenue of $14.
46 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same period last year, the company posted $2.
91 earnings per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year.
Check Out Our Latest Report on AbbVie AbbVie Price Performance NYSE ABBV opened at $196.25 on Friday. The company has a market cap of $346.
55 billion, a PE ratio of 58.23, a P/E/G ratio of 2.49 and a beta of 0.
64. AbbVie has a 52-week low of $135.85 and a 52-week high of $198.
30. The company has a debt-to-equity ratio of 7.93, a quick ratio of 0.
83 and a current ratio of 0.94. The firm’s 50 day moving average price is $181.
44 and its 200-day moving average price is $173.93. AbbVie Announces Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, August 15th.
Shareholders of record on Monday, July 15th were issued a $1.55 dividend. The ex-dividend date of this dividend was Monday, July 15th.
This represents a $6.20 annualized dividend and a yield of 3.16%.
AbbVie’s payout ratio is 183.98%. Insider Buying and Selling at AbbVie In other AbbVie news, Chairman Richard A.
Gonzalez sold 66,500 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.
00. Following the transaction, the chairman now directly owns 446,599 shares in the company, valued at approximately $83,299,645.48.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . In other news, Chairman Richard A. Gonzalez sold 66,500 shares of the business’s stock in a transaction that occurred on Monday, August 5th.
The shares were sold at an average price of $186.52, for a total value of $12,403,580.00.
Following the sale, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink .
Also, Chairman Richard A. Gonzalez sold 282,845 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $175.
00, for a total transaction of $49,497,875.00. Following the completion of the sale, the chairman now directly owns 513,099 shares in the company, valued at $89,792,325.
The disclosure for this sale can be found here . 0.25% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows Several institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Vermillion & White Wealth Management Group LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $26,000. Fairway Wealth LLC acquired a new stake in AbbVie during the 2nd quarter worth $26,000.
Ridgewood Investments LLC acquired a new stake in AbbVie during the 2nd quarter worth $27,000. Able Wealth Management LLC acquired a new stake in AbbVie during the 4th quarter worth $33,000. Finally, IFS Advisors LLC acquired a new stake in AbbVie during the 1st quarter worth $36,000.
Institutional investors and hedge funds own 70.23% of the company’s stock. About AbbVie ( Get Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Recommended Stories Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter .
.
